SPL Mapping FHIR R5 Implementation Guide
0.2.1 - Build CI United States of America flag

SPL Mapping FHIR R5 Implementation Guide, published by HL7 International / Biomedical Research and Regulation. This guide is not an authorized publication; it is the continuous build for version 0.2.1 built by the FHIR (HL7® FHIR® Standard) CI Build. This version is based on the current content of https://github.com/HL7/fhir-spl/ and changes regularly. See the Directory of published versions

Example Composition: These highlights do not include all the information needed to use LANTUS safely and effectively. See full prescribing information for LANTUS. <br/> <br/>LANTUS<sup>®</sup> (insulin glargine injection) for subcutaneous injection <br/>Initial U.S. Approval: 2000

Page standards status: Informative

Generated Narrative: Composition LantusInjectionLabelComposition

VersionNumber: 11

identifier: Uniform Resource Identifier (URI)/urn:uuid:6328c99d-d75f-43ef-b19e-7e71f91e57f6

status: Final

type: HUMAN PRESCRIPTION DRUG LABEL

date: 2021-01-27

author: Organization sanofi-aventis U.S. LLC

title: These highlights do not include all the information needed to use LANTUS safely and effectively. See full prescribing information for LANTUS. <br/> <br/>LANTUS<sup>®</sup> (insulin glargine injection) for subcutaneous injection <br/>Initial U.S. Approval: 2000